AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27403608 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified corn-soy blend
Number of subjects: 4
Study 27403608 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified LNS with milk protein base
Number of subjects: 4
Study 27403608 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified LNS with soy protein base
Number of subjects: 4
Study 27403608 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementary food)
Number of subjects: 4
Study 26273669 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1167
Study 23062314 — intervention group
Group type: EXPERIMENTAL
Intervention: Widened spatial QRS-T angle
Number of subjects: 4453
Study 23062314 — intervention group
Group type: COMPARATOR
Intervention: Normal spatial QRS-T angle
Number of subjects: 4453
Study 21609640 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 48
Study 21609640 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptives (COC)
Number of subjects: 48
Study 21609640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LNG-IUS and COC
Number of subjects: 48
Study 18840113 — intervention group
Group type: EXPERIMENTAL
Intervention: Light sedation (MAAS 3-4)
Number of subjects: 36
Study 18840113 — intervention group
Group type: COMPARATOR
Intervention: Heavy sedation (MAAS 1-2)
Number of subjects: 36
Study 16511927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinical management approach (experimental group)
Number of subjects: 288
Study 16511927 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment approach (control group)
Number of subjects: 288
Study 12930331 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL-CSC
Number of subjects: 35
Study 12930331 — intervention group
Group type: COMPARATOR
Intervention: PDL alone
Number of subjects: 35
Study 10710841 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent incentives based on cocaine-free urinalysis results
Number of subjects: 70
Study 10710841 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent incentives (independent of urinalysis results)
Number of subjects: 70
Study 8939038 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitation of faces
Number of subjects: 0
Study 8939038 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (concentration on faces)
Number of subjects: 0
Study 1608327 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention of basic technical skills
Number of subjects: 25
Study 3899166 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 3899166 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 0
Study 3899166 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 0
Study 28813701 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of cervical length (CL) provided to the study group; CL measurement performed 24‐48 h after admission. If CL was >25 mm, early discharge within 12‐24 h from randomization was recommended.
Number of subjects: 149
Study 28813701 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded to CL measurement).
Number of subjects: 149
Study 27635609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml per 400 ml of 5% glucose solution, intravenously, 1 time a day for 10 days, then 2 tablets 2 times a day for a month)
Number of subjects: 52
Study 27635609 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 52
Study 23899830 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 2177
Study 23899830 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 2177
Study 23899830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2177
Study 23350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoid + Aronia extract
Number of subjects: 0
Study 23350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoid + Larix extract + Hibiscus extract
Number of subjects: 0
Study 23350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoid + Silybum extract
Number of subjects: 0
Study 23350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoid + Q10 + Rosa majalis extract
Number of subjects: 0
Study 23350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia + Raponticum extracts
Number of subjects: 0
Study 23350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Larix + Hibiscus extracts
Number of subjects: 0
Study 23350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizandra + Aronia extracts
Number of subjects: 0
Study 20429751 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) in dementia patients with frontal lobe symptoms
Number of subjects: 23
Study 20429751 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 Alzheimer patients without frontal lobe symptoms and 10 normal controls, N=20)
Number of subjects: 23
Study 18534620 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 456
Study 18534620 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 456
Study 16188154 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radio-chemotherapy (NVB + DDP plus radiotherapy)
Number of subjects: 64
Study 16188154 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (NVB + DDP)
Number of subjects: 64
Study 12358338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil (two puffs of 2 mg)
Number of subjects: 25
Study 12358338 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (two puffs of 100 microg)
Number of subjects: 25
Study 12358338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nedocromil and salbutamol
Number of subjects: 25
Study 12358338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10425589 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCyte
Number of subjects: 32
Study 10425589 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 32
Study 7574126 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified discharge instructions
Number of subjects: 423
Study 7574126 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 423
Study 2176235 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg twice (group A)
Number of subjects: 103
Study 2176235 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once (group B)
Number of subjects: 103
Study 7000106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 12.5 mg kg‐1
Number of subjects: 60
Study 7000106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 25 mg kg‐1
Number of subjects: 60
Study 7000106 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 0.15 mg kg‐1
Number of subjects: 60
Study 7000106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 60
Study 31715047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-race ECG
Number of subjects: 301
Study 31715047 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-race ECG
Number of subjects: 301
Study 30370450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU) after memory retrieval
Number of subjects: 61
Study 30370450 — intervention group
Group type: COMPARATOR
Intervention: Intranasal oxytocin (40 IU) without retrieval
Number of subjects: 61
Study 30370450 — intervention group
Group type: COMPARATOR
Intervention: Placebo after memory retrieval
Number of subjects: 61
Study 28024952 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-boost EVD vaccine
Number of subjects: 0
Study 28024952 — intervention group
Group type: COMPARATOR
Intervention: Real-time dynamic modelling
Number of subjects: 0
Study 27228986 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 51523
Study 25142791 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMP-DM
Number of subjects: 1248
Study 25142791 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1248
Study 21950726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/d
Number of subjects: 30
Study 20630497 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharated chewing gum
Number of subjects: 449
Study 20630497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum
Number of subjects: 449
Study 20630497 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum
Number of subjects: 449
Study 20630497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (second experiment)
Number of subjects: 449
Study 20630497 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (second experiment)
Number of subjects: 449
Study 17694386 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low dose plasma exchange
Number of subjects: 33
Study 17694386 — intervention group
Group type: COMPARATOR
Intervention: Alternate day plasma exchange
Number of subjects: 33
Study 15780697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment (not specified dosage or duration)
Number of subjects: 276
Study 12410505 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous metallic commissurotome (PMC)
Number of subjects: 80
Study 12410505 — intervention group
Group type: COMPARATOR
Intervention: Inoue balloon mitral valvuloplasty (BMV)
Number of subjects: 80
Study 12410505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 80
Study 12410505 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral commissural splitting
Number of subjects: 80
Study 9446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sugiura (Hirashima) procedure
Number of subjects: 104
Study 9446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Late postoperative period (after Hirashima procedure)
Number of subjects: 104
Study 9446376 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy volunteers)
Number of subjects: 104
Study 9446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein thrombosis
Number of subjects: 104
Study 7942937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent very-low-calorie diet (VLCD) of 400 to 500 kcal per day for 12 weeks, alternating with a balanced low-calorie diet (LCD) of 1,000 to 1,000 kcal per day throughout the year-long treatment.
Number of subjects: 93
Study 7942937 — intervention group
Group type: COMPARATOR
Intervention: Balanced low-calorie diet (LCD) of 1,000 to 1,000 kcal per day throughout the year-long treatment.
Number of subjects: 93
Study 7942937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VLCD and LCD)
Number of subjects: 93
Study 7942937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent VLCD
Number of subjects: 93
Study 2897388 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine, 40 mg once daily
Number of subjects: 280
Study 2897388 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine, 60 mg twice daily
Number of subjects: 280
Study 2897388 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 280
Study 30100375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (1.0 mg/kg intravenously weekly for the first 28-day cycle, then on days 1 and 15 of subsequent cycles)
Number of subjects: 372
Study 30100375 — intervention group
Group type: COMPARATOR
Intervention: Vorinostat (400 mg daily)
Number of subjects: 372
Study 26477659 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (N=33)
Number of subjects: 56
Study 26477659 — intervention group
Group type: COMPARATOR
Intervention: Active control group (N=23)
Number of subjects: 56
Study 26477659 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent studying
Number of subjects: 56
Study 26477659 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline memory performance
Number of subjects: 56
Study 26477659 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term memory task performance
Number of subjects: 56
Study 24815533 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 463
Study 24815533 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg QD
Number of subjects: 463
Study 24815533 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg QD
Number of subjects: 463
Study 24815533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 22205424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy for flight phobia (specific dosage and duration not mentioned)
Number of subjects: 45
Study 22205424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy for flight phobia
Number of subjects: 45
Study 20650798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-use ProTaper instruments
Number of subjects: 203
Study 20650798 — intervention group
Group type: COMPARATOR
Intervention: Standard stainless steel K-file
Number of subjects: 203
Study 18541590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation, mean daily dose of 86 microg (3440 IU) adjusted every 2 months based on serum 25(OH)D concentration.
Number of subjects: 138
Study 18541590 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer simulations for optimal daily dose of vitamin D(3).
Number of subjects: 138
Study 18541590 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected dose-response curves for different baseline 25(OH)D concentrations.
Number of subjects: 138
Study 15777857 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA) at lung, shenmen, thalamus and hip points
Number of subjects: 54
Study 15777857 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (4 non-acupuncture points on the auricular helix)
Number of subjects: 54
Study 15777857 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 54
Study 15777857 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 54
Study 15611418 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial or complete replacement of amalgam fillings in Group A (13 patients)
Number of subjects: 80
Study 15611418 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial or complete replacement of amalgam fillings in Group B (8 patients)
Number of subjects: 80
Study 15611418 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial or complete replacement of amalgam fillings in Group C (2 patients)
Number of subjects: 80
Study 15611418 — intervention group
Group type: COMPARATOR
Intervention: Control Group D (20 patients) with signs of allergic contact dermatitis
Number of subjects: 80
Study 11054193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled flunisolide 2 mg/d
Number of subjects: 104
Study 11054193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 9089000 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (tablet Krewel)
Number of subjects: 18
Study 9089000 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation 1 (suspension Krewel)
Number of subjects: 18
Study 9089000 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation 2 (tablet Muskel Trancopal)
Number of subjects: 18
Study 8447567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium 50 mg on the evening before operation and 25 mg on the morning of the operation
Number of subjects: 100
Study 8447567 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg p.o. on the evening before the operation
Number of subjects: 100
Study 8447567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium
Number of subjects: 100
Study 8447567 — intervention group
Group type: COMPARATOR
Intervention: i.m. premedication with promethazine, pethidine and atropine
Number of subjects: 100
Study 3082613 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone treatment (100 micrograms thyroxin)
Number of subjects: 1973
Study 3137624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 15 mg
Number of subjects: 45
Study 3137624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 45
Study 3137624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 45
Study 3137624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 45
Study 3137624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29307152 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week core stability training (CST) program
Number of subjects: 69
Study 29307152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 28790042 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regulation of tracheal cuff pressure using a pneumatic device
Number of subjects: 0
Study 28790042 — intervention group
Group type: COMPARATOR
Intervention: Intermittent control of tracheal cuff pressure (once every 8 hours)
Number of subjects: 0
Study 26328636 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol treatment
Number of subjects: 176
Study 26328636 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 176
Study 24037880 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin D₃
Number of subjects: 67
Study 24037880 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU/d vitamin D₃
Number of subjects: 67
Study 24037880 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU/d vitamin D₃
Number of subjects: 67
Study 21798556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid sequence intubation (RSI) with glycopyrrolate, thiopental, suxamethonium, and remifentanil
Number of subjects: 34
Study 21798556 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 34
Study 19467538 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH)
Number of subjects: 0
Study 19467538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian factors
Number of subjects: 0
Study 16978371 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15
Study 16978371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14678061 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (n=105)
Number of subjects: 200
Study 14678061 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention education-as-usual control condition (n=95)
Number of subjects: 200
Study 11382830 — intervention group
Group type: COMPARATOR
Intervention: 0.75% ropivacaine alone
Number of subjects: 30
Study 11382830 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine + 1 microg/kg clonidine
Number of subjects: 30
Study 9243351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol gadolinium/kg
Number of subjects: 18
Study 9243351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 mmol gadolinium/kg
Number of subjects: 18
Study 9243351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mmol gadolinium/kg
Number of subjects: 18
Study 8299238 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy diet alone (SD)
Number of subjects: 20
Study 8299238 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy diet plus 5 g/day of fish oil (SD + FO)
Number of subjects: 20
Study 2834502 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Kabi 2165)
Number of subjects: 79
Study 2834502 — intervention group
Group type: COMPARATOR
Intervention: Non-fractionated heparin
Number of subjects: 79
Study 29649036 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline alexithymia measured by the 26-item Toronto Alexithymia Scale (TAS-26)
Number of subjects: 5586
Study 29649036 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for age, sex, and occupational status
Number of subjects: 5586
Study 29649036 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for all covariates, using binary TAS-26 cut-offs or TAS-26 subscores
Number of subjects: 5586
Study 27287330 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning
Number of subjects: 282
Study 27287330 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 282
Study 25222264 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-class clothing (business-suit)
Number of subjects: 0
Study 25222264 — intervention group
Group type: COMPARATOR
Intervention: Lower-class clothing (sweatpants)
Number of subjects: 0
Study 24120213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 531
Study 24120213 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 531
Study 20598373 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART CAMP intervention
Number of subjects: 42
Study 20598373 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 42
Study 19096768 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 years' monotherapy)
Number of subjects: 0
Study 19096768 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (5 years' monotherapy)
Number of subjects: 0
Study 19096768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (2 years tamoxifen followed by 3 years letrozole)
Number of subjects: 0
Study 19096768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (2 years letrozole followed by 3 years tamoxifen)
Number of subjects: 0
Study 16870078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg tablets
Number of subjects: 423
Study 16870078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 12662419 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 299
Study 12662419 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 299
Study 12662419 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (untreated)
Number of subjects: 299
Study 10229430 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nonsteroidal antiinflammatory drug (NSAID)
Number of subjects: 443